Additionally, markers such as GalNac-T3 (N-acetylgalactosaminyltransferase 3), prostate-specific membrane antigen (PSMA), hepsin, and prostate cancer antigen 3 (PCA3) assist in differentiating PCa from benign prostatic hyperplasia. This evidence concerns the gene PCA3 and posterior cortical atrophy.